Search

Displaying results 3401 - 3410 of 10000 in total
  1. Drug

    Bucetin

    go.drugbank.com/drugs/DB13278
    ApprovedWithdrawn

    Bucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.[A175636]

  2. Drug

    Enavogliflozin

    go.drugbank.com/drugs/DB18970
    Investigational

    Enavogliflozin is under investigation in clinical trial NCT06399835 (Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis).

    Categories: Drugs Used in Diabetes
  3. Drug

    Hypochlorous acid

    go.drugbank.com/drugs/DB14135
    Investigational

    An oxyacid of chlorine (HClO) containing monovalent chlorine that acts as an oxidizing or reducing agent.

    Categories: Compounds used in a research, industrial, or household settingProducts: AN XIN Disinfectant, INCARE All in one Plus
  4. Drug

    Mibefradil

    go.drugbank.com/drugs/DB01388
    ApprovedWithdrawn

    Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.

  5. Drug

    CYT006-AngQb

    go.drugbank.com/drugs/DB05739
    Investigational

    CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. … It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure

  6. Drug

    Choline C-11

    go.drugbank.com/drugs/DB09563
    Approved

    Choline C 11 Injection is a radioactive diagnostic agent for positron emission tomography (PET) imaging of pat ients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magneti...

  7. Drug

    Efonidipine

    go.drugbank.com/drugs/DB09235
    Investigational

    It has also been studied in atherosclerosis and acute renal failure [A32001]. This drug is also known as NZ-105, and several studies have been done on its pharmacokinetics in animals [L1456]. … Initially, it was marketed in 1995 under the trade name, _Landel_. The drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001].

  8. Drug

    Clotiazepam

    go.drugbank.com/drugs/DB01559
    ApprovedIllicit

    Clotiazepam is a thienodiazepine, not approved for sale in the U.S. or Canada, but has been approved in the U.K. It is a schedule IV drug in Canada.

  9. Drug

    Otelixizumab

    go.drugbank.com/drugs/DB05496
    Investigational

    Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. … Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance

  10. Drug

    Brecanavir

    go.drugbank.com/drugs/DB04887
    Investigational

    In July 2006, Vertex indicated that it expected GSK to initiate phase III trials of the drug in 2007. … In December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug.